Are clinical trials into emerging drugs for the treatment of alpha-1 antitrypsin deficiency providing promising results?

Click to increase image sizeClick to decrease image size

Declaration of interest

A M Turner has had grants and/or honoraria from CSL Behring, Grifols, Vertex, Takeda, Beam, GSK, AstraZeneca, and Chiesi.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.